• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 6:09:51 AM ET
    $OBLN
    Medical/Dental Instruments
    Health Care
    Get the next $OBLN alert in real time by email
    SC 13G/A 1 d123402dsc13ga.htm SC 13G/A SC 13G/A
    OMB APPROVAL
    OMB Number:   3235-0145 
    Expires:   February 28, 2010 
    Estimated average burden
    hours per response   10.4 

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (AMENDMENT NO 6)*

     

     

    Obalon Therapeutics, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    67424L209

    (CUSIP Number)

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    Page 1 of 9 Pages


    Cusip No. 67424L209    13G    Page 2 of 9 Pages

     

      1    

      NAME OF REPORTING PERSONS

     

      InterWest Partners X, LP (“IWP X”)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      California

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      398,974

       6   

      SHARED VOTING POWER

     

      0

       7   

      SOLE DISPOSITIVE POWER

     

      398,974

       8   

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      398,974 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.1% (2)

    12  

      TYPE OF REPORTING PERSON

     

      PN

     

    (1)

    The shares are owned by IWP X and include (i) 380,224 shares of Common Stock and (ii) 18,750 shares of Common Stock issuable pursuant to common stock purchase warrants.

    (2)

    Based upon 7,770,698 shares of the Issuer’s Common Stock outstanding as of November 2, 2020, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 6, 2020.

     

    Page 2 of 9 Pages


    Cusip No. 67424L209    13G    Page 3 of 9 Pages

     

      1    

      NAME OF REPORTING PERSONS

     

      InterWest Management Partners X, LLC (the General Partner of InterWest Partners X, LP)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      California

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      398,974

       6   

      SHARED VOTING POWER

     

      0

       7   

      SOLE DISPOSITIVE POWER

     

      398,974

       8   

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      398,974 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.1% (2)

    12  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    The shares are owned by IWP X and include (i) 380,224 shares of Common Stock and (ii) 18,750 shares of Common Stock issuable pursuant to common stock purchase warrants.

    (2)

    Based upon 7,770,698 shares of the Issuer’s Common Stock outstanding as of November 2, 2020, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 6, 2020.

     

    Page 3 of 9 Pages


    Cusip No. 67424L209    13G    Page 4 of 9 Pages

     

      1    

      NAME OF REPORTING PERSONS

     

      Keval Desai (a Venture Member of InterWest Management Partners X, LLC)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      398,974

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      398,974

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      398,974

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.1%

    12  

      TYPE OF REPORTING PERSON

     

      IN

    Neither the filing of this statement on Schedule 13G nor any of its contents shall be deemed to constitute an admission by Keval Desai that he is the beneficial owner of any of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

     

    Page 4 of 9 Pages


    Cusip No. 67424L209    13G    Page 5 of 9 Pages

     

      1    

      NAME OF REPORTING PERSONS

     

      Gilbert H. Kliman (a Managing Director of InterWest Management Partners X, LLC)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      398,974

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      398,974

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      398,974

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.1%

    12  

      TYPE OF REPORTING PERSON

     

      IN

    Neither the filing of this statement on Schedule 13G nor any of its contents shall be deemed to constitute an admission by Gilbert H. Kliman that he is the beneficial owner of any of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

     

    Page 5 of 9 Pages


    Cusip No. 67424L209    13G    Page 6 of 9 Pages

     

      1    

      NAME OF REPORTING PERSONS

     

      Khaled A. Nasr (a Venture Member of InterWest Management Partners X, LLC)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      398,974

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      398,974

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      398,974

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.1%

    12  

      TYPE OF REPORTING PERSON

     

      IN

    Neither the filing of this statement on Schedule 13G nor any of its contents shall be deemed to constitute an admission by Khaled A. Nasr that he is the beneficial owner of any of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

     

    Page 6 of 9 Pages


    Cusip No. 67424L209    13G    Page 7 of 9 Pages

     

    ITEM 1.

     

    (a)

    NAME OF ISSUER : Obalon Therapeutics, Inc.

     

    (b)

    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICE:

    5421 Avenida Encinas, Suite F, Carlsbad, CA 92008

    ITEM 2.

     

    (a)

    NAME OF PERSON(S) FILING:

    InterWest Partners X, LP (“IWP X”)

    InterWest Management Partners X, LLC (“IMP X”)

    Keval Desai (“Desai”)

    Gilbert H. Kliman (“Kliman”)

    Khaled A. Nasr (“Nasr”)

     

    (b)

    ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

    467 First Street, Suite 201, Los Altos, CA 94022

     

    (c)

    CITIZENSHIP/PLACE OF ORGANIZATION:

     

    IWP X:    California
    IMP X:    California
    Desai:    United States
    Kliman:    United States
    Nasr:    United States

     

    (d)

    TITLE OF CLASS OF SECURITIES: Common Stock

     

    (e)

    CUSIP NUMBER: 67424L209

    ITEM 3. NOT APPLICABLE.

     

    Page 7 of 9 Pages


    Cusip No. 67424L209    13G    Page 8 of 9 Pages

     

    ITEM 4. OWNERSHIP.

     

         IWP X     IMP X (1)     Desai (2)  

    Beneficial Ownership

         398,974  (3)      398,974  (3)      398,974  (3) 

    Percentage of Class

         5.1 % (4)      5.1 % (4)      5.1 % (4) 

    Sole Voting Power

         398,974       398,974       0  

    Shared Voting Power

         0       0       398,974  

    Sole Dispositive Power

         398,974       398,974       0  

    Shared Dispositive Power

         0       0       398,974  

     

         Kliman (2)     Nasr (2)  

    Beneficial Ownership

         398,974  (3)      398,974  (3) 

    Percentage of Class

         5.1 % (4)      5.1 % (4) 

    Sole Voting Power

         0       0  

    Shared Voting Power

         398,974       398,974  

    Sole Dispositive Power

         0       0  

    Shared Dispositive Power

         398,974       398,974  

     

    (1)

    IMP X is the general partner of IWP X.

    (2)

    Kliman is a Managing Director of IMP X. Desai and Nasr are Venture Members of IMP X. The Managing Directors and Venture Members of IMP X share voting and investment control over shares held by IWP X.

    (3)

    The shares are owned by IWP X and include (i) 380,224 shares of Common Stock and (ii) 18,750 shares of Common Stock issuable pursuant to common stock purchase warrants.

    (4)

    Based upon 7,770,698 shares of the Issuer’s Common Stock outstanding as of November 2, 2020, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 6, 2020.

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

    Not applicable.

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

    Under certain circumstances set forth in the limited liability company operating agreement of IMP X, the members of such limited liability company have the right to receive dividends from, or the proceeds from the sale of, the common stock of Issuer beneficially owned by such limited liability company.

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

    Not applicable.

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    No reporting person is a member of a group as defined in section 240.13d-1(b)(1)(iii)(H) of the Act.

    ITEM 9. NOTICE OF DISSOLUTION OF THE GROUP.

    Not applicable.

     

    Page 8 of 9 Pages


    Cusip No. 67424L209    13G    Page 9 of 9 Pages

     

    ITEM 10. CERTIFICATION.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    EXHIBITS

    Joint Filing Statement attached as Exhibit A.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 12, 2021
    INTERWEST PARTNERS X, LP
    By:   InterWest Management Partners X, LLC, its General Partner
    By:   /s/ Gilbert H. Kliman by Karen A. Wilson, Power of Attorney
      Managing Director
    INTERWEST MANAGEMENT PARTNERS X, LLC
    By:   /s/ Gilbert H. Kliman by Karen A. Wilson, Power of Attorney
      Managing Director
    By:   /s/ Keval Desai by Karen A. Wilson, Power of Attorney
    Name:   Keval Desai
    By:   /s/ Gilbert H. Kliman by Karen A. Wilson, Power of Attorney
    Name:   Gilbert H. Kliman
    By:   /s/ Khaled A. Nasr
    Name:   Khaled A. Nasr

     

    Page 9 of 9 Pages

    Get the next $OBLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OBLN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OBLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Obalon Therapeutics upgraded by Alliance Global Partners

    Alliance Global Partners upgraded Obalon Therapeutics from Neutral to Buy

    2/18/21 7:35:42 AM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    $OBLN
    SEC Filings

    View All

    Obalon Therapeutics, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - ReShape Lifesciences Inc. (0001427570) (Filer)

    7/2/21 4:05:32 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    Obalon Therapeutics, Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - OBALON THERAPEUTICS INC (0001427570) (Filer)

    6/15/21 5:11:09 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    Obalon Therapeutics, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - OBALON THERAPEUTICS INC (0001427570) (Filer)

    6/15/21 12:20:14 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    $OBLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Announce Anticipated Closing of Merger

    SAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 15, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced today the anticipated closing of their previously announced merger to be effective after the close of the market today, June 15, 2021. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market on Wednesday, June 16, 2021, under the name ReShape Lifesciences Inc. and the trading symbol "RSLS."Immediately following the effective time of the merger, existing ReShape stockholders will own 51% and existing Obalon stockholders will own 49% of the outstanding shares of common stock of the

    6/15/21 12:05:00 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Update on Status of Pending Merger

    SAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced today that the parties anticipate the closing of their previously announced merger to occur promptly after approval of their pending Nasdaq listing application. While there can be no assurance that the listing application will be approved, Nasdaq approval is the sole remaining condition to closing in the merger agreement (other than conditions that the parties anticipate being satisfied at the closing). Upon the closing of the merger, shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital M

    6/8/21 7:30:00 AM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    Reminder: Obalon Therapeutics Continues to Urge Stockholders to Vote FOR All Proposals Related to Merger with ReShape Lifesciences

    SAN DIEGO, CA / ACCESSWIRE / May 24, 2021 / Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, is taking this opportunity to remind its stockholders to vote on all the proposals related to the proposed merger with ReShape Lifesciences Inc. in advance of the upcoming reconvened special meeting of Obalon stockholders (the "Special Meeting") on May 25, 2021, at 8:30 a.m. PT.All stockholders are highly encouraged to vote by phone or email on this critical transaction. Without the required stockholder approval, the merger will not be able t

    5/24/21 7:30:00 AM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    $OBLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by ARMISTICE CAPITAL, LLC

    4 - ReShape Lifesciences Inc. (0001427570) (Issuer)

    6/29/21 9:44:48 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    SEC Form 3: STANKOVICH THOMAS claimed ownership of 2,613 units of Common Stock

    3 - ReShape Lifesciences Inc. (0001427570) (Issuer)

    6/24/21 5:29:11 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by McDougal Lori Courtney

    3 - ReShape Lifesciences Inc. (0001427570) (Issuer)

    6/24/21 5:13:50 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    $OBLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Obalon Therapeutics, Inc. (Amendment)

    SC 13G/A - ReShape Lifesciences Inc. (0001427570) (Subject)

    6/30/21 6:16:56 AM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Obalon Therapeutics, Inc. (Amendment)

    SC 13D/A - ReShape Lifesciences Inc. (0001427570) (Subject)

    6/30/21 6:10:33 AM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Obalon Therapeutics, Inc.

    SC 13D - ReShape Lifesciences Inc. (0001427570) (Subject)

    6/25/21 4:21:09 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care

    $OBLN
    Financials

    Live finance-specific insights

    View All

    Obalon Announces Fourth Quarter and Full Year 2020 Financial Results

    SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2020. On November 10, 2020, the Company signed a non-binding term sheet for merger with ReShape Lifesciences Inc. and, on January 20, 2021, announced that a definitive agreement had been signed on January 19, 2020 for a merger with ReShape Lifesciences Inc. Financial results for the fourth quarter of 2020Revenue for the fourth quarter of 2020 w

    3/12/21 7:12:24 PM ET
    $OBLN
    Medical/Dental Instruments
    Health Care